Scholarlink

Background <p>Subclavian venous occlusion is a frequent complication of transvenous cardiac implantable electronic device (CIED) implantation, with reported incidences exceeding 30%. Although often asymptomatic, chronic total occlusion (CTO) creates a major technical barrier during device revision, particularly for cardiac resynchronization therapy (CRT) upgrades. Conventional strategies such as lead extraction or contralateral tunneling may increase procedural risk or compromise future vascular access. Subclavian CTO venoplasty is a minimally invasive alternative to re-establish ipsilateral access.</p> Methods <p>We describe a single-center series of six patients (ages 62–78&#xa0;years) who underwent percutaneous subclavian, axillary, or brachiocephalic venoplasty to facilitate CIED upgrade or lead revision. Our approach favored ipsilateral upper-extremity access (typically basilic vein) with a 0.018-inch platform using polymer-jacketed guidewires and microcatheters for CTO crossing. Serial balloon angioplasty (4.0–10.0&#xa0;mm; 40–80&#xa0;mm length range) was performed using stepwise inflation (nominal pressure with escalation as needed up to rated burst pressure per device specifications) to restore venous patency.</p> Results <p>Technical success was achieved in all six cases (100%), enabling four CRT implantations, one left bundle branch area pacing (LBBAP) implant, and one dual-chamber lead revision. No major intraprocedural complications occurred; one patient developed a self-resolving chest wall hematoma. Procedure time ranged from 116 to 240&#xa0;min. Among CRT recipients, QRS duration narrowed (mean reduction 45 ± 18&#xa0;ms). Follow-up (2–12&#xa0;months) demonstrated stable lead parameters and no clinical evidence of recurrent occlusion.</p> Conclusion <p>In this small series, subclavian/central venous CTO venoplasty using a brachial-first, 0.018-inch CTO-oriented strategy was feasible and enabled successful ipsilateral CIED revision while preserving vascular access. Larger studies are needed to better define the success rate and safety relative to the extraction or subclavian/device pocket access only approach.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Subclavian chronic total occlusion angioplasty facilitates cardiac implantable electronic device upgrades: A single-center case series

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月13日

查看全文
  • Richard Amoateng,
  • Emmanuel Olumuyide,
  • Xiarepati Tieliwaerdi,
  • Sruti Prathivadhi-bhayankaram,
  • Sukit Ringwala,
  • Dana Johnson,
  • Joaquim Spadoni Barboza

摘要

Background

Subclavian venous occlusion is a frequent complication of transvenous cardiac implantable electronic device (CIED) implantation, with reported incidences exceeding 30%. Although often asymptomatic, chronic total occlusion (CTO) creates a major technical barrier during device revision, particularly for cardiac resynchronization therapy (CRT) upgrades. Conventional strategies such as lead extraction or contralateral tunneling may increase procedural risk or compromise future vascular access. Subclavian CTO venoplasty is a minimally invasive alternative to re-establish ipsilateral access.

Methods

We describe a single-center series of six patients (ages 62–78 years) who underwent percutaneous subclavian, axillary, or brachiocephalic venoplasty to facilitate CIED upgrade or lead revision. Our approach favored ipsilateral upper-extremity access (typically basilic vein) with a 0.018-inch platform using polymer-jacketed guidewires and microcatheters for CTO crossing. Serial balloon angioplasty (4.0–10.0 mm; 40–80 mm length range) was performed using stepwise inflation (nominal pressure with escalation as needed up to rated burst pressure per device specifications) to restore venous patency.

Results

Technical success was achieved in all six cases (100%), enabling four CRT implantations, one left bundle branch area pacing (LBBAP) implant, and one dual-chamber lead revision. No major intraprocedural complications occurred; one patient developed a self-resolving chest wall hematoma. Procedure time ranged from 116 to 240 min. Among CRT recipients, QRS duration narrowed (mean reduction 45 ± 18 ms). Follow-up (2–12 months) demonstrated stable lead parameters and no clinical evidence of recurrent occlusion.

Conclusion

In this small series, subclavian/central venous CTO venoplasty using a brachial-first, 0.018-inch CTO-oriented strategy was feasible and enabled successful ipsilateral CIED revision while preserving vascular access. Larger studies are needed to better define the success rate and safety relative to the extraction or subclavian/device pocket access only approach.